Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Core Points - Apollomics Inc. has successfully appealed a delisting notification from Nasdaq, resulting in the cancellation of the scheduled hearing and the continuation of its listing on the Nasdaq Stock Market [1] - The company is focused on developing oncology therapies, particularly its lead program vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer [2] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company based in California, specializing in oncology drug development aimed at treatment-resistant cancers [2] - The lead drug candidate, vebreltinib, is currently undergoing a Phase 2 multicohort clinical trial in the United States and other countries [2]